Skip to content
SJM

The J. M. Smucker Company

The J. M. Smucker Company Q1 FY2026 earnings call

August 27, 2025 · fiscal period ended 2025-07

EPS · actual vs est

$1.90 / $1.94Miss -2.1%

Revenue · actual vs est

$2.11B / $2.12BMiss -0.5%
Ask about this call

Summary

Generated 2025-08-27

Management highlights

  • Coffee segment: Current pricing outlook is mid-20s, including early winter tariffs, with volume impact in low to mid-teens. - EPS: Full-year guidance midpoint remains $9, first quarter is softest, second quarter has additional coffee costs but profit expectations for coffee are in line after absorbing tariffs. - Milk Bone: Expected to return to growth in the second half, supported by advertising, innovation, seasonals, and tactical price points/promo. - Sweet Baked Snacks: SKU rationalization ongoing with a $30M savings benefit, $10M in Q4 FY26 and $20M in FY27, profitability to improve sequentially. - Hostess portfolio: Stabilization efforts ongoing, with brands like Donette showing growth. - Free cash flow: Increased to $975M for FY26 due to one big beautiful bill act, to be used for debt pay down. - GLP-one drugs: No meaningful impact on categories yet, portfolio positioned to address potential issues.
View in transcript ↓

Segment performance

No detailed absolute financial performance or revenue contribution % for product segments was explicitly stated in a structured manner during the call.

View in transcript ↓

Guidance

  • Coffee: Pricing now mid-20s, volume impact low to mid-teens, net sales low to mid-teens. - Full-year: EPS guidance midpoint $9, profit shifted to later quarters due to coffee costs and tariffs. - Free cash flow: Increased to $975M, aiming for three times leverage by FY27. - Sweet Baked Snacks: SKU rationalization to have $30M savings, $10M in Q4 FY26, $20M in FY27.
View in transcript ↓

Risks

  • Tariffs on green coffee impacting pricing and profitability. - Consumer caution affecting pet product consumption. - Potential impact of GLP-one drugs on food categories, though not seen yet.
View in transcript ↓

Q&A highlights

Q: Updated expectation on pricing benefit in coffee segment and if included in August price increase?

A: Pricing now mid-20s, includes early winter tariffs, volume low to mid-teens, segment growth low to mid-teens.

Q: Shift in EPS phasing?

A: Full-year guidance midpoint unchanged, offset by increased tariffs, first quarter coffee costs higher than anticipated, second quarter has additional costs.

Q: Coffee elasticity and top line impact?

A: Pricing actions, May pricing better, August at historical, winter higher elasticity, net $0.05 worse.

Q: Milk Bone growth in second half?

A: Strong comps, brand support with advertising, innovation, seasonals, promo.

Q: SKU rationalization impact on Sweet Baked Snacks volume?

A: No impact in Q1, benefit $30M, $10M in Q4 FY26, $20M in FY27.

Q: Guidance cadence and back half improvement?

A: Profit shifted to later quarters, midpoint guidance intact.

Q: SKU rationalization earnings impact?

A: $30M savings, Q4 FY26 $10M, FY27 $20M, profitability improves sequentially.

Q: Confidence in fiscal 2027 outlook?

A: Coffee margins in Q4, Hostess stabilization, growth brands, tariff navigation.

Q: Price vs volume mix and coffee pricing ramp?

A: Coffee mid-20s, Q1 18%, later quarters higher, sales ramp sequentially better.

Q: Free cash flow and deleveraging?

A: Increased to $975M, ongoing benefit, used for debt pay down.

Q: 2Q net sales outlook and segment improvement?

A: Coffee momentum, Uncrustables, pet growth, Sweet Baked Snacks stabilization.

Q: Tariff exemptions and impact?

A: Monitor, no current relief, timing impact on P&L.

Q: GLP-one drugs impact?

A: No meaningful impact, categories not affected, portfolio positioned.

Q: Hostess SKU reduction sales impact?

A: Focus on growth brands, Donette growth offsets.

Q: Tariff exemption relief and P&L impact?

A: Relief would revise 50¢ impact, timing factors.

View in transcript ↓

Key numbers

Reported versus consensus

Earnings calendar feed

MetricReportedConsensusDeltaPrior year
EPS$1.90$1.94-2.1%$2.44
Revenue$2.11B$2.12B-0.5%$2.13B

Transcript

August 27, 2025

Full transcript unavailable for redistribution

The structured summary above covers the available call sections. Full transcript text is not included on this page.

Continue exploring

Prior quarters

This page presents the stored structured earnings-call summary and deterministic earnings calendar values. How this is generated. For informational purposes only; not investment advice.